Kornimate/medical-research-clean huggingface dataset:
ability of cardio q for prediction of hypotension

Conditions: Prostate Cancer

Summary: evaluation the ability of each indicator of cardio q in predicting hypotension after position changes in robot-assisted laparoscopic radical prostatectomy

hypotension is common in patients who undergo general anesthesia. hypotension may cause hypoperfusion in the organs of the body, resulting in ischemia and increased mortality within one year. hypotension may occur at any time during general anesthesia but may also occur with changes in posture. in robot-assisted laparoscopic radical prostatectomy, hypotension often occurs when posture is changed from a trendelenburg position to a supine position. however there is no data regarding which hemodynamic parameters can predict hypotension induced by position change. excessive administration of the fluid in steep trendelenburg position may lead to fluid overload and lead to complications such as pulmonary edema. thus, the predictors are should be identified to manage patients without fluid overload. therefore, the aim of this study is to investigate the parameters of cardio q which are useful for predicting hypotension after position change.

Eligibility criteria:
inclusion criteria: patients undergoing robot-assisted laparoscopic radical prostatectomy asa 1-3 exclusion criteria: patients that * unstable angina, left ventricular ejection fraction \<40% * severe vascular disease * insertion type : pacemaker / defibrillator * autonomic nervous system diseases * when esophageal varices are present * if the subject includes a person who can not read the written consent (eg, illiterate, foreigner, etc.)

Keywords: robotic surgery position cardio q hypotension
gastrointestinal myoelectric activity protocol, the g-tech eeng protocol

Conditions: Gastrointestinal Diseases

Summary: a feasibility study for monitoring and recording gastrointestinal (gi) myoelectric activity in subjects with suspected or diagnosed irritable bowel syndrome (ibs) and reports of gi pain and asymptomatic subjects without ibs and gi pain.

this single arm, prospectively enrolling, non-randomized feasibility study has been designed to transcutaneously detect and monitor myoelectric intestinal signals temporally associated with the symptoms of patients who report pain and have suspected or diagnosed ibs, and in controls \[subjects without suspected ibs or diagnosis of ibs and prior and/or current complaints of pain\].

Eligibility criteria:
general eligibility criteria: general inclusion criteria * willing and able to provide informed consent; * eighteen (18) years of age or older; * willing and able to follow a specified study procedure regimen; * no known allergy to commercially available food or drink required by specified study procedure regimen; * willing and able to recline and remain still during the recordings. general exclusion criteria * subject has an implantable device such as a pacemaker, defibrillator, nerve stimulator, insulin pump, automatic analgesic pump, or other automated implanted medical device; * known allergy to isopropyl (rubbing) alcohol; * known allergy to ag/agcl electrodes; * known allergy to glue adhesive (electrode adhesive); * dietary restrictions not permitting intake of food or drink required by this protocol; * dietary restrictions not permitting four (4) hour fasting period prior to start of myoelectric recording; * subject is pregnant or suspects pregnancy; * open sores or wounds on the abdomen; * any injury in or around the area of electrode placement that would cause pain with gentle pressure required for electrode and lead wire placement; * weight \> 300 lbs (136 kg) (excess weight can interfere with quality of the signals). ibs with complaints of gi pain eligibility criteria ibs with complaints of pain inclusion criteria all answers must be "yes" to the all of the following inclusion criteria prior diagnosis of ibs and complaints of gi pain ibs with complaints of pain exclusion criteria all answers must be "no" to the all of the following exclusion criteria functional dyspepsia; no reports of gi pain, past or present. control subjects eligibility criteria subjects who do not have a prior diagnosis of functional gi disorder control subjects inclusion criteria all answers must be "yes" to the all of the following inclusion criteria no prior diagnosis ibs; no complaints of gi pain. control subjects exclusion criteria all answers must be "no" to the all of the following exclusion criteria current diagnosis of any gi disorder; current or recent complaints of gi pain.

Keywords: irritable bowel syndrome ibs gastrointestinal pain gastrointestinal functional disorder
effect of high-flow therapy in long-term oxygen therapy

Conditions: Chronic Obstructive Pulmonary Disease Severe; Interstitial Lung Disease; Chronic Respiratory Failure With Hypoxia

Summary: this is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device lumis hft) during one year in people with long-term oxygen therapy (ltot) for chronic obstructive pulmonary disease (copd) or interstitial lung disease (ild).

this is a registry-based, randomized, controlled clinical trial of patients with ltot for copd or ild recruited using the swedish national registry for respiratory failure (swedevox) in collaboration with a research network within the swedish respiratory society. the trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year. the purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in sweden, who have high risk of adverse events and mortality.

Eligibility criteria:
inclusion criteria: * age 40 years or older * ongoing ltot: prescribed for at least 15 hours per day; and since at least 28 days as registered in swedevox * copd or ild as main underlying reason for ltot * oxygen concentrator as stationary oxygen source in the home including night-time * body mass index (bmi) \< 35 kg/m2 exclusion criteria: * current or previous treatment with home hfot * current treatment with home mechanical ventilation * current treatment with home cpap * hospitalized during the last 2 weeks * current smoking or contact with flames * self-reported average use of the ltot \< 15h per day (24 hours) * paco2 (breathing air at rest) \> 8 kpa * strong clinical suspicion of obstructive sleep apnea (osa) or obesity-related hypoventilation syndrome (ohs) (as judged by the responsible staff) * inability to participate in the study procedures (as judged by the staff) * not eligible for continuing ltot due to other reason (as judged by the staff) * expected survival less than 3 months (as judged by the staff)
interprofessional collaborative communication in acute care hospital teams

Conditions: Disease; Delivery of Healthcare

Summary: collaborative practice may improve patient outcomes in specific disease conditions and health care settings. the script programme is an intervention to implement informal, but structured, communication etiquette between members of interprofessional ward-based clinical teaching units (ctus) in general internal medicine (gim) hospital divisions.

a recent literature review commissioned by health canada for the inter-professional education for collaborative patient-centred practice initiative (iecpcp) reported evidence that collaborative practice improves patient outcomes in specific populations. interprofessional collaborative teaching and practicing are poorly articulated in the literature, however. studies are needed that can develop a trial-based body of evidence to support education and practice of effective interprofessional care. the script project will attempt to develop sustainable transformation in the conduct, learning and evaluation of interprofessional teamwork in the toronto academic health science network (tahsn). script has investigated interprofessional work relations in general internal medicine units at tahsn hospitals using fieldwork observations and interview methods. these data were foundational for script's design of a unit-based staff intervention intended to promote more--and more-effective--informal interprofessional communication and collaboration between gim staff members outside of traditional, structured meeting times like morning report and bullet rounds. the intervention is designed as part of a pragmatic trial. we will ask gim division staff of intervention teams to implement a 4-step communication protocol in face-to-face, patient-related interaction. the steps are: 1. introduce oneself by name; 2. state one's role or responsibility in relation to the patient under discussion; 3. describe the issue, problem, or plan relating to the target patient; 4. elicit feedback from the other participant(s) in the interaction with a prompt, e.g., "do you have any concerns," or, "is there something else i should consider?" the intervention will be evaluated as a cluster randomized controlled trial among five large toronto (canada) teaching hospitals. two medical clinical teaching units and associated ward teams of nurses and other health professionals from each hospital's gim division will be allocated at random to enact the intervention. two other gim ctus in each hospital will continue their usual interprofessional practice, without intervention. in total, there are 20 ctus, 10 in the treatment group and 10 in the control group. intervention ctus will be compared with control ctus on the outcomes of interest.

Eligibility criteria:
inclusion criteria: * patients admitted to divisions of general internal medicine * health care providers working in divisions of general internal medicine

Keywords: interprofessional collaboration teamwork general internal medicine cluster randomized
investigation of the effect of ocrelizumab on peripheral lymphocyte immunophenotypes with suppressive capacity in ms

Conditions: Multiple Sclerosis

Summary: this is a 24-month, prospective, exploratory, observational study to investigate immune phenotypes in patients with ms following treatment with ocrelizumab.

this is a 24-month, prospective, exploratory, observational study to investigate immune phenotypes in patients with ms following treatment with ocrelizumab. the study will be conducted on health sciences university istanbul haydarpaşa numune training and research hospital, neurology department. the decision to treat with ocrelizumab must be made prior to and independently from the proposal to enroll the patient into this study and in line with the summary of product characteristics (smpc) approved by the turkish ministry of health. data will be recorded at screening visit, baseline visit (month 0), second visit on 6th month, third visit on 12th month and last visit (end of the study \[eos\]) on 24th month according to local clinic practice. optional ad hoc visits could be conducted if relapse of ms or infection after vaccination occurs during ocrelizumab treatment. the duration of the study for each patient will be 24 months.

Eligibility criteria:
inclusion criteria: * adults (≥18 years old) with a diagnosis of relapsing forms of multiple sclerosis (rms) or primary progressive multiple sclerosis (ppms) according to the 2017 revised mcdonald criteria. * previous ms treatment with at least one of other dmt(\*). the patients can be without treatment before switching until the end of wash-out period of previous dmt(s) or until lymphocytes parameter is in normal range. * previous treatment change with the reasons inefficacy, safety related issues or lack of compliance. * decision to initiate ocrelizumab therapy (in accordance with the product characteristics approved in turkey) has already been taken for the treatment of ms patient as part of routine clinical practice. the decision to treat with ocrelizumab must be made prior to and independently from the proposal to enroll the patient into this study. * agreed and signed informed consent. (\*) a dmt is defined as any of the following drugs: teriflunomide, interferon beta 1a, interferon beta 1b, peginterferon beta 1a, glatiramer acetate, fingolimod, daclizumab, alemtuzumab, cladribine, dimethyl fumarate, and natalizumab. exclusion criteria: * previously treated with anti-cd20 therapy (rituximab, atacicept, belimumab or ofatumumab). * medical history of a malignancy, active infection (including hepatitis b virus) or chronic inflammatory disease. * medical history or use of any medication other than a dmt as defined above which may affect immunophenotypes of the participants.

Keywords: ocrelizumab disease modifying therapy t cell b cell
ugist: ultrasound guided internal jugular short-term central venous catheters tunneling

Conditions: Infection; Bacteremia

Summary: the purpose of the study is to determine if tunneling standard short-term central lines for a short distance under the skin, with the assistance of ultrasound imaging, reduces the risk of central line infections for catheters placed in the neck vein. previous work has shown that these lines can be tunneled without ultrasound guidance. we wish to determine if the use of ultrasound makes the tunneling procedure safer and easier.

more than 250,000 vascular catheter-related bloodstream infections occur annually in the usa with a mortality ranging from 12% to 25% in critically ill patients. it is also widely accepted that the internal jugular site is associated with a higher risk of catheter related infection if compared with the subclavian site. therefore, the benefit of catheter tunneling was best seen at the internal jugular site as described by j f timsit in 1996 in his prospective randomized multicentre study where it significantly decreased the rate of catheter related sepsis from 11.4% to 3.4%. at the same time, tunneling catheters did not increase the rate of mechanical complications such as pneumothorax, hematoma, or arterial puncture, but it almost doubled the rate of technical difficulties, such as problems with advancing the catheter or multiple puncture sites, at that time it was a blind technique. now, and with the introduction of the ultrasound guidance in our routine central line insertions, we would like to evaluate its benefit in reducing the technical difficulty and mechanical complications that used to be encountered while tunneling the short term central venous catheters at the internal jugular site.

Eligibility criteria:
inclusion criteria: * adult icu patients. * likely to need the line for 48 hours. * standard central venous catheter. exclusion criteria: * mechanical impedance (e.g c-spine protection). * absent internal jugular vessel on u/s. * previous line still in place. * presence of overlying skin or tissue infection or mass. * tricuspid valve vegetation. * tumor extending to the right atrium. * persistent coagulopathy. * newly inserted pacemaker leads. * recent carotid endarterectomy on same side. * no ultrasound facility available. * patients requiring special lines (e.g. dialysis).

Keywords: tunneling short term central venous catheters ultrasound guided internal jugular assess safety and improve technical difficulty
lann-study: lantus, amaryl, novorapid, novomix study

Conditions: Diabetes Mellitus Type II

Summary: many diabetics gain weight while on insulin therapy. in this study, we evaluate the efficacy of the combination of glimepiride and short-acting insulin on weight control and glucose control. in this study, 150 diabetics whose diabetic control is inadequate while on maximal oral treatment will be randomized to either the new combination treatment or twice daily injections with a mixture of short- and longacting insulin or once-daily injection with a basal insulin analog. the study will compare glucose control and weight gain during a year after randomisation between the three treatments.

diabetic patients failing on maximal oral treatment usually switch to twice daily administration of a mixture of short- and longacting insulin. although this improves glycemic control, it is generally accompanied by a substantial gain in body weight. this may lead to an increase in body fat resulting in a worsening of insulin resistance, leading to an increase in insulin dose needed to maintain glycemic control. the combination of glimepiride(amaryl) and short-acting insulin (novorapid) is thought to attain glycemic control with a smaller increase in body weight. in this randomized controlled trial, 150 diabetics failing on maximal oral treatment will be randomized to preprandial use of novorapid combined with amaryl at 20.00 hours, twice daily novomix 30, or once daily lantus. metformin will be continued. in the year after randomisation, patients will be followed for glycemic control, body weight, body composition, recorded number of hypoglycemic events, plasma lipid levels, basal and stimulated c-peptide levels and adverse effects.

Eligibility criteria:
inclusion criteria: * failing maximal oral treatment, defined as mean fasting blood glucose over 8 mmol/l and hba1c over 7.5% for three months or more * bmi 25 - 35 kg/m2 * fasting plasma c-peptide level over 0.3 nmol/l * stable metformin and sulfonylurea dose for at least three months * stable weight for at least three months (change maximal 2 kg) exclusion criteria: * fasting glucose over 25 mmol/l * use of alpha-glucosidase inhibitors or thiazolidinediones in the two months preceding the study * renal or liver failure defined as serum creatinine over 150 micromol/l, liver enzymes over 1.5 upper normal limit * heart failure * pregnancy * alcohol more than two units per day * inflammatory or infectious diseases * unstable chronic disease * discontinuation of smoking within three months of randomisation date * allergy for or intolerance of glimepiride or novorapid.

Keywords: diabetes failing oral treatment weight gain
research on the clinical effect of effective prescription in treating unstable angina.

Conditions: Unstable Angina

Summary: this study evaluates the clinical efficacy of the famous prescription in the treatment of unstable angina pectoris. all of the patients will be divided into 4 arms according to their syndrome type. one of the arms will be treated by conventional western medicine, the other three will be treated by different chinese herbal medicine prescription at the base of conventional western medicine.

xuefu zhuyu decoction has the function of activating qi and promoting blood circulation, which will be used to treat patients with qi stagnation and blood stasis syndrome. gualouxiebaibanxia decoction compounded with danshen decoction has the effect of promoting blood circulation and resolving phlegm, so it will be used for patients taht belong to phlegm and blood stasis type. shuanghe decoction has the function of supplementing qi and activating blood circulation, which will be used to treat patients with qi deficiency and blood stasis syndrome.

Eligibility criteria:
inclusion criteria: * participants diagnosed with coronary heart disease through coronary angiography or coronary cta; patients have at least one of these symptoms: 1. the stability of the nature of angina pectoris changes, that is, frequent attacks of angina pectoris, serious degree and prolonged duration; 2. angina pectoris during rest; 3. the recent occurrence of angina pectoris caused by mild physical activity in the last month. exclusion criteria: * patients dignosed with stable angina; patients with acute myocardial infarction; chest pain caused by congenital heart disease, valvular heart disease, severe neurosis or arrhythmia; the heart function grade is iii or iv; patients with acute cerebral infarction; patients complicated with other serious primary diseases; patients with acute infection in recent 2 weeks; uncontrolled hypertension (the resting blood pressure \>160/95mmhg within one week); diabetics emerged with serious diabetic complications; patients can't finish the questionnaire due to abnormal mental and nervous or mental disorders; pregnant or lactating women.

Keywords: unstable angina traditional chinese medicine
a biomarker screening protocol for participants with solid tumors

Conditions: Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic; Non-Small Cell Carcinoma of Lung, TNM Stage 4; Advanced Breast Cancer; Advanced Lung Carcinoma; NSCLC; NSCLC, Recurrent; NSCLC Stage IV; Relapsed Cancer; Relapse/Recurrence; Recurrent Breast Cancer; Recurrent NSCLC; Platinum-resistant Ovarian Cancer; Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Endometrioid Tumor; High Grade Serous Carcinoma; Ovarian Epithelial Cancer

Summary: biomarker screening protocol for preliminary eligibility determination for adoptive t-cell therapy trials:this is a decentralized, multi-site, us-based biomarker screening study to identify participants who have specific disease indications and tumor expression of target(s) of interest that may inform eligibility for active and future lyell clinical trials. no investigational treatments will be administered in this non-interventional screening study. only previously obtained archival tumor tissue will be allowed on this study for biomarker analysis. fresh tumor biopsies are not permitted on this study. the study will be conducted virtually and participants will utilize telehealth and e-consent modules. if participants tumors express the biomarkers of interest they can be referred to open and enrolling clinical trials. participation on the screening study does not guarantee enrollment or treatment on an interventional clinical trial.


Eligibility criteria:
inclusion criteria: 1. participants aged ≥ 18 years at time of informed consent 2. able to provide informed consent 3. histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumor malignancy.the sponsor will indicate which solid tumor disease indications are open to enrollment. 4. ability to provide a tumor tissue sample collected within 3 years prior to enrollment. the sample must consist, at minimum, of 5 freshly cut, unstained 4-5 μm sections cut from a formalin-fixed paraffin-embedded (ffpe) tissue block. the sample must contain sufficient tumor tissue to allow for the evaluation of biomarker expression exclusion criteria: 1. prior solid organ transplantation 2. prior treatment with any adoptive cell therapy 3. uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with a clinical study, as judged by the investigator or sponsor's medical monitor

Keywords: biomarker screening immunotherapy car-t car t-cell therapy car t car t-cell ror1 ror1+ ror1 positive cell therapy relapsed refractory solid tumor advanced metastatic breast cancer lung cancer triple negative breast cancer non small cell lung cancer ovarian cancer endometrial cancer